News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Cellares to automate TScan's TCR therapy manufacturing ahead of 2026 trial
Cellares will test its Cell Shuttle and Cell Q systems to automate production of TSC-101, a gene-modified T cell therapy for blood cancer, before the drug enters pivotal trials in Q2 2026.
Eli Lilly bets $1.9B on Ascidian's gene-editing tech for kidney disease
Eli Lilly signed a $1.9 billion partnership with Ascidian Therapeutics to develop RNA exon editing treatments for monogenic kidney diseases. The deal marks Lilly's third major genetic medicine commitment this week.
Daraxonrasib Doubles Pancreatic Cancer Survival in Phase 3 Trial
Revolution Medicine's once-daily RAS inhibitor cut death risk by 60% in 500 patients with aggressive pancreatic cancer. Three other therapies showed clinical wins at ASCO 2026 in lung, blood, and prostate cancers.
Korea's biotech labs lure global pharma away from centralized support
Ecolab opened its first Asian bioprocessing lab in Korea this spring, part of a broader industry shift toward regional expertise. Korea now generates 2.2% of global continuous bioprocessing revenue.
McMaster lab finds first antibiotic that avoids all known bacterial resistance
Manikomycin targets a ribosomal site no antibiotic has exploited before, meaning bacteria have evolved no defenses against it. The compound works on multidrug-resistant bacteria and is the fourth new candidate from the lab in 14 months.
Cellares Automates TScan's TCR-T Manufacturing for Late-Stage AML Trial
TScan and Cellares will evaluate fully automated production of TSC-101, a donor-derived T cell therapy for blood cancers. The pilot targets commercial readiness ahead of a pivotal trial expected to start Q2 2026.
Incyte Expands Genesis AI Drug Deal to $1B+ on Early Wins
Incyte and Genesis Molecular AI doubled down on their partnership after 15 months showed results on hard-to-drug targets. The deal now covers five programs with potential payouts exceeding $1 billion—here's what actually worked.
Hookworm Engineered to Produce Antibodies Inside Human Host
Researchers at WashU Medicine genetically modified hookworms to secrete therapeutic antibodies. The preclinical proof-of-concept shows parasites can act as long-term drug factories inside the body.
90-120 min of strength training cuts death risk by 13%, study finds
A 30-year Harvard-led study published in the British Journal of Sports Medicine shows strength training at 90-120 minutes weekly reduces all-cause mortality by 13%. Combined with aerobic exercise, the benefit climbs to 53-58%.
1.5M deaths yearly from unsafe food, WHO warns after 194-country analysis
WHO studied two decades of data across 194 countries and found contaminated food kills 1.5 million people annually, with under-fives at 3x higher risk. Africa and Southeast Asia account for 75% of cases.
Seven PE Firms Race for 25% of India's Largest Maternity Chain at $1B Valuation
Warburg Pincus, KKR, TPG, and others bid for stake in Cloudnine. The maternity and pediatric hospital operator reported ₹2,000 crore revenue and ₹300 crore EBITDA in FY26.
Three travelers from Ebola regions placed in 21-day home isolation in India
Chhattisgarh officials placed three asymptomatic returnees from Democratic Republic of Congo, Ethiopia, and Uganda under home isolation as precaution after WHO declared Ebola a public health emergency.